FIELD: medicine; pharmacology.
SUBSTANCE: invention gives the description of transdermal medicine containing agent reservoir; effective amount of lazophoxiphen and its pharmaceutically acceptable salts; effective amount of agent permeability intensifier containing effective amount of lower alkanole and effective amount of glycerine monooleate. Besides, devices of active agent introduction are described. Such devices can be produced as matrix plaster (medicinal agent in adhesive) or reservoir plaster (medicinal agent in liquid or polymer reservoir along perimeter as stripes, or as self-adhesive over layer). In addition this invention refers to methods of treatment and prevention of estrogen deficiency disorders.
EFFECT: easy-to-use; continuous treatment course; strict control of medicinal agent concentration in blood and general improvement of therapeutic treatment.
13 cl, 5 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TRANSDERMAL SYSTEM FOR VARENICLINE | 2006 |
|
RU2388461C2 |
| TRANSDERMAL PLASTER FOR INTRODUCING 17-DEACETYLNORHESTIMATE SEPARATELY OR IN COMBINATION WITH ESTROGEN | 1996 |
|
RU2177311C2 |
| TETRABENAZINE TRANSDERMAL DELIVERY DEVICE | 2019 |
|
RU2800536C2 |
| AGENT AND METHOD FOR TRANSDERMAL DELIVERY OF OESTROGEN | 2009 |
|
RU2526186C2 |
| ADMINISTRATION OF ANDROGENIC STEROIDS TO WOMEN BY NON-ORAL ROUTE | 2000 |
|
RU2234920C2 |
| TRANSDERMAL DONEPEZIL DELIVERY SYSTEM | 2017 |
|
RU2779471C2 |
| ESTRADIOL-CONTAINING TRANSDERMAL THERAPEUTIC SYSTEM | 1994 |
|
RU2140784C1 |
| TRANSDERMAL GRANISETRON | 2004 |
|
RU2355387C2 |
| METHOD FOR ENHANCING OF TESTOSTERONE AND ANALOGOUS STEROID LEVELS IN FEMALES | 2001 |
|
RU2286787C2 |
| DEXTROMETHORPHAN TRANSDERMAL DELIVERY DEVICE | 2018 |
|
RU2795729C2 |
